RICOLINOSTAT (ACY-1215), THE FIRST SELECTIVE HDAC6 INHIBITOR, COMBINED WITH POMALIDOMIDE AND DEXAMETHASONE SHOWS PROMISING EARLY PHASE 2 RESULTS IN RELAPSED-AND-REFRACTORY MULTIPLE MYELOMA: ACE-MM-102

被引：0

作者：

Raje, N. ^{[1
]}

Terpos, E. ^{[2
]}

Cole, C. ^{[3
]}

Bahlis, N. ^{[4
]}

Bensinger, W. ^{[5
]}

Libby, E. ^{[5
]}

Palumbo, A. ^{[6
]}

Lonial, S. ^{[7
]}

Sandhu, I. ^{[8
]}

Arce-Lara, C. ^{[9
]}

Jagannath, S. ^{[10
]}

Valent, J. ^{[11
]}

Rosko, A. ^{[12
]}

Reece, D. ^{[13
]}

Supko, J. ^{[1
]}

Tamang, D. ^{[14
]}

Jones, S. ^{[14
]}

Wheeler, C. ^{[14
]}

Markelewicz, R. ^{[14
]}

Richardson, P. ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Univ Athens, Athens, Greece

[3] Univ Michigan, Ann Arbor, MI 48109 USA

[4] Univ Calgary, Calgary, AB, Canada

[5] Univ Washington, Seattle, WA 98195 USA

[6] Univ Turin, Turin, Italy

[7] Emory Univ, Atlanta, GA 30322 USA

[8] Univ Alberta, Edmonton, AB T6G 2M7, Canada

[9] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[10] Mt Sinai Hosp, New York, NY 10029 USA

[11] Cleveland Clin, Cleveland, OH 44106 USA

[12] Ohio State Univ, Columbus, OH 43210 USA

[13] Univ Toronto, Toronto, ON, Canada

[14] Acetylon Pharmaceut Inc, Boston, MA USA

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

S813

引用

页码：328 / 328

页数：1

共 16 条

[1] Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study)
Raje, Noopur S.
Bensinger, William
Cole, Craig E.
Lonial, Sagar
Jagannath, Sundar
Arce-Lara, Carlos E.
Valent, Jason
Rosko, Ashley E.
Harb, Wael A.
Sandhu, Irwindeep
Bahlis, Nizar J.
Reece, Donna
Terpos, Evangelos
Supko, Jeffrey
Tamang, David
Jones, Simon S.
Wheeler, Catherine
Markelewicz, Robert J., Jr.
Richardson, Paul G.
BLOOD, 2015, 126 (23)
[2] RICOLINOSTAT (ACY-1215) THE FIRST SELECTIVE HDAC6 INHIBITOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED & REFRACTORY MULTIPLE MYELOMA: PHASE 1B & EARLY PHASE 2 RESULTS
Raje, N.
Bensinger, W.
Lebovic, D.
Lonial, S.
Jagannath, S.
Acre-Lara, C.
Rosko, A.
Harb, W.
Bahlis, N.
Supko, J.
Tamang, D.
Jones, S.
Wheeler, C.
Richardson, P.
HAEMATOLOGICA, 2015, 100 : 86 - 86
[3] Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combonation with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed -and Refractory Multiple Myeloma: Phase lb Results (ACE-MM-101 Study)
Yee, Andrew J.
Bensinger, William
Voorhees, Peter M.
Berdeja, Jesus G.
Richardson, Paul G.
Supko, Jeffrey
Tamang, David
Jones, Simon S.
Wheeler, Catherine
Markelewicz, Robert J., Jr.
Raje, Noopur S.
BLOOD, 2015, 126 (23)
[4] Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study)
Vogl, Dan T.
Raje, Noopur S.
Jagannath, Sundar
Richardson, Paul G.
Hari, Parameswaran
Orlowski, Robert Z.
Supko, Jeffrey
Tamang, David
Jones, Simon S.
Wheeler, Catherine
Markelewicz, Robert J., Jr.
Lonial, Sagar
BLOOD, 2015, 126 (23)
[5] Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple Myeloma
Yee, Andrew J.
Voorhees, Peter M.
Bensinger, William
Berdeja, Jesus G.
Supko, Jeffrey G.
Richardson, Paul G.
Tamang, David
Jones, Simon S.
Patrick, Gretchen
Wheeler, Catherine
Raje, Noopur
BLOOD, 2014, 124 (21)
[6] Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM)
Vogl, Dan T.
Raje, Noopur
Hari, Parameswaran
Jones, Simon S.
Supko, Jeffrey G.
Leone, Gina
Wheeler, Catherine
Orlowski, Robert Z.
Richardson, Paul G.
Lonial, Sagar
Tamang, David
Jagannath, Sundar
BLOOD, 2014, 124 (21)
[7] Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study)
Niesvizky, Ruben
Richardson, Paul G.
Yee, Andrew J.
Nooka, Ajay K.
Raab, Marc S.
Shain, Kenneth H.
Gabrail, Nashat Y.
Matous, Jeffrey
Agarwal, Amit B.
Hoffman, James
Madan, Sumit
Pagel, John M.
San Miguel, Jesus
Moreau, Philippe
Mateos, Maria-Victoria
Facon, Thierry
Tamang, David
Jones, Simon S.
Markelewicz, Robert J., Jr.
Wheeler, Catherine
Trede, Nikolaus S.
Raje, Noopur
Terpos, Evangelos
Bensinger, William I.
BLOOD, 2016, 128 (22)
[8] Selective Inhibition of HDAC6 with a New Prototype Inhibitor (ACY-1215) Overcomes Bortezomib Resistance In Multiple Myeloma (MM)
Santo, Loredana
Hideshima, Teru
Kung, Andrew L.
Jarpe, Matthew
Cirstea, Diana
Patel, Kishan
Pozzi, Samantha
Tseng, Jen C.
Rodig, Scott J.
Bradner, James
Anderson, Kenneth C.
Jones, Simon
Raje, Noopur
BLOOD, 2010, 116 (21) : 1235 - 1236
[9] ACY-1215, a selective inhibitor of HDAC6, synergizes with immunomodulatory drugs (IMiDs) to induce apoptosis of multiple myeloma (MM) cells
Quayle, Steven N.
Tamang, David
Yang, Min
Jones, Simon S.
CANCER RESEARCH, 2014, 74 (19)
[10] ACY-241, A NOVEL, ORAL TABLET HDAC6 SELECTIVE INHIBITOR COMBINES SAFELY WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (ACE-MM-200 STUDY)
Niesvizky, R.
Richardson, P.
Gabrail, N.
Madan, S.
Yee, A.
Shain, K.
Hoffman, J.
Pagel, J.
Bensinger, W.
Nooka, A.
Agarwal, A.
Matous, J.
Raab, M. S.
Terpos, E.
Bhol, K.
Tamang, D.
Jones, S. S.
van Duzer, J.
Wheeler, C.
Trede, N. S.
Raje, N.
HAEMATOLOGICA, 2016, 101 : 524 - 525

← 1 2 →